This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [01.11.2019] – [with additional studies] sallieq | home:food:aim_health:aging [02.11.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== | + | ====== |
Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
Line 7: | Line 7: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
+ | |||
+ | | ||
+ | |||
+ | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
| | ||
+ | |||
+ | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
+ | |||
+ | Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
- | | ||
- | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | + | ==== General research on aging ==== |
- | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes | + | When using off-label Olmesartan, |
+ | |||
+ | These articles have identified holistic vitamin D supplementation with or without calcium is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence | ||
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| | ||
Line 102: | Line 111: | ||
=== Long term treatment === | === Long term treatment === | ||
- | Data suggest 40 & 80 mg olmesartan | + | |
// | // | ||
{{tag> | {{tag> | ||